23:03 , Jul 11, 2019 |  BC Extra  |  Preclinical News

Elicio's cancer vaccine boosts CAR Ts for solid tumors

The MIT group behind cancer start-up Elicio reported that its technology for boosting immune responses to cancer vaccines can also prime CAR T cells to kill solid tumors. CAR T cell therapies have been approved...
00:12 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Otsuka's mitochondrial uncoupler for metabolic, cardiovascular indications

DISEASE CATEGORY: Endocrine/metabolic; cardiovascular INDICATION: Diabetes; metabolic syndrome; stroke; hypertension Rat and mouse studies suggest the mitochondrial uncoupler OPC-163493 could help treat Type I and Type II diabetes, metabolic syndrome, stroke and hypertension. In three...
19:21 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting bacterial tpl for diabetic nephropathy

DISEASE CATEGORY: Renal INDICATION: Diabetic nephropathy; renal failure Patient sample and mouse studies suggest inhibiting bacterial tpl could help treat diabetic nephropathy and renal failure. In tissue samples from diabetes patients, serum levels of phenyl...
19:53 , May 2, 2019 |  BC Extra  |  Company News

CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be...
23:28 , Mar 27, 2019 |  BC Extra  |  Financial News

Elicio raises $30M to target cancer vaccines to the lymph nodes

Elicio launched Wednesday with $30 million in funding and an immunotherapy strategy aimed at getting cancer vaccines into the lymph nodes, a location that orchestrates immune responses but has been hard to target directly. Elicio...
17:34 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Abraxane as adjuvant misses primary in resected pancreatic cancer

Celgene said Abraxane nab-paclitaxel plus gemcitabine missed the primary endpoint of improving disease-free survival vs. gemcitabine alone in the Phase III apact trial evaluating the drugs as adjuvant therapy for patients with surgically resected pancreatic...
21:17 , Mar 5, 2019 |  BC Extra  |  Company News

Intarcia licenses Numab's autoimmune therapy

Ahead of an NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab exclusive, worldwide rights to autoimmune disorder therapy, ND016. ND016 is a trispecific antibody fragment that blocks...
18:43 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat mucopolysaccharidosis II (MPS II, Hunter syndrome) and SB-318 to...
00:54 , Feb 8, 2019 |  BC Extra  |  Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) lost $3.71 (31%) to $8.31 Thursday after the company reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat...
13:51 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus In vitro , cell culture and mouse studies identified three TNC-based fusion proteins against S. aureus leukocidin ED or S. aureus γ-hemolysin AB that could help prevent and treat Staphylococcus infections. Screening of...